Last December, a multi-society Delphi consensus reported on the new nomenclature and definitions of fatty liver disease [1]. Accordingly, the previous terms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which rely on exclusionary confounder terms as well as the potential use of stigmatizing language, were replaced by metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Today, MASLD/MASH represent by far the most common liver disease worldwide in parallel with the increasing prevalence of obesity and metabolic syndrome (insulin resistance and diabetes, arterial hypertension, central obesity, and dyslipidemia) [2–4].
